MiniMed Group (MMED) SEC filings document the regulatory record of a Nasdaq-listed diabetes technology company focused on insulin delivery systems, CGMs, sensors, algorithms, and app-connected diabetes management. MiniMed's filings include annual reports, quarterly reports, proxy statements, and Form 8-K material event reports.
For MMED, the most relevant filings often relate to medical device operations and newly public company governance. Annual reports and 10-Q filings can describe business structure, risk factors, capital structure, financial results, clinical and regulatory matters, and disclosures tied to MiniMed's separation from Medtronic. Form 8-K filings have covered financial results, board appointments, executive compensation plans, officer departures, cybersecurity-related disclosures, and other material events.
Proxy statements are useful for reviewing director elections, auditor ratification, advisory compensation votes, and governance matters. Form 4 insider transaction filings can show reported purchases, sales, or equity awards by directors and officers when such filings are submitted. 10-K and 10-Q reports are especially important for understanding how MiniMed reports its diabetes technology business after becoming a public company.
AI-powered summaries can translate dense filing language into plain-English explanations, while real-time EDGAR updates can surface new MMED filings as they are released. These summaries are most useful when reviewing long annual reports, quarterly updates, proxy statements, and insider transaction disclosures.
MiniMed Group, Inc. announced that the U.S. Food and Drug Administration has cleared the MiniMed Flex™, a next-generation, discreet, smartphone-controlled insulin pump. The clearance came several months earlier than anticipated and will allow earlier commercialization of this key product.
Development of MiniMed Flex™ was funded in part by affiliates of Blackstone Life Sciences Advisors L.L.C. Under their agreement, during the first two years following U.S. regulatory approval and commercial launch, Blackstone will receive the greater of a mid-to-high single digit royalty percentage on applicable net sales or a minimum payment of $157 million. MiniMed expects to recognize a one-time charge of $157 million in the fourth quarter of fiscal year 2026 related to these future payments.
MiniMed Group, Inc. officer John Gyurci reported receiving 15,322 shares of common stock on a grant or award basis, with no cash price per share. These shares represent restricted stock units in MiniMed that were created by converting prior Medtronic equity awards in connection with MiniMed’s separation from Medtronic.
The units were granted under the 2026 MiniMed Group, Inc. Long Term Incentive Plan and vest in three equal installments on January 26, 2027, January 26, 2028, and January 26, 2029. Following this equity award conversion, Gyurci directly holds 15,322 MiniMed shares, including shares to be issued upon future vesting of restricted stock units.
MiniMed Group, Inc. insider Chandrasena Gillian reported multiple grants of common stock on March 11, 2026, all classified as awards rather than market purchases. Each grant reflects MMED restricted stock units received at a price of $0.00 per share.
According to the footnotes, these MMED RSUs were issued when certain Medtronic plc equity awards held by the insider were converted into MiniMed awards in connection with the company’s separation from Medtronic effective March 9, 2026, under the 2026 MiniMed Group, Inc. Long Term Incentive Plan. The converted RSUs vest over time, with tranches scheduled between July 28, 2026 and July 28, 2028, making this a compensation-related equity conversion, not an open‑market stock trade.
MiniMed Group, Inc. reported a compensation-related stock grant to officer Wills Courtney Nelson tied to the company’s separation from Medtronic. On March 11, 2026, Nelson received several awards of MiniMed common stock as part of the conversion of prior Medtronic equity awards into MiniMed restricted stock units under the 2026 Long Term Incentive Plan.
The awards were granted at $0.00 per share and represent time-vesting RSUs that will settle in MiniMed shares as they vest. According to the footnotes, these RSUs result from an equity award conversion process using average trading prices of both Medtronic and MiniMed shares, with vesting dates ranging from July 31, 2026 through April 28, 2028.
MiniMed Group, Inc. reported that officer Dianaty Ali received multiple grants of common stock on March 11, 2026, all with a grant price of $0.00 per share. These are classified as awards rather than open-market purchases.
The grants represent MMED restricted stock units created when prior Medtronic restricted and performance share awards were converted following MiniMed’s separation from Medtronic effective March 9, 2026, under an Employee Matters Agreement. The MMED RSUs were issued under the 2026 MiniMed Group, Inc. Long Term Incentive Plan and vest on several dates between July 31, 2026 and October 29, 2028, including single-date vesting and a three-installment schedule.
MiniMed Group, Inc. EVP and Chief Financial Officer Chad Spooner received multiple equity awards in connection with MiniMed’s separation from Medtronic plc. On March 11, 2026, he was granted time-vesting restricted stock units (MMED RSUs) that were created by converting prior Medtronic restricted stock and performance share awards under an Employee Matters Agreement tied to the March 9, 2026 separation.
The grants cover 70,896 shares vesting on April 28, 2028, 127,609 shares vesting in three equal installments on July 28, 2026, July 28, 2027 and July 28, 2028, and 70,896 shares vesting on July 28, 2028. All awards were issued at a reported price of $0.00 per share as compensation, not as open-market purchases or sales, and were made under the 2026 MiniMed Group, Inc. Long Term Incentive Plan.
MiniMed Group, Inc. reported that Chief Executive Officer Dallara Que received multiple equity awards in the form of MiniMed common stock–denominated restricted stock units on March 11, 2026. These awards were granted at a price of $0.00 per share as compensation, not through open-market purchases.
The footnotes explain that existing Medtronic restricted stock units and performance share units held by Que were converted into MiniMed RSUs in connection with MiniMed’s separation from Medtronic plc, under an Employee Matters Agreement. The converted RSUs were issued under the 2026 MiniMed Group, Inc. Long Term Incentive Plan and vest on various dates between July 31, 2026 and April 28, 2028, with one grant vesting in two installments on March 10, 2026 and March 10, 2027.
MiniMed Group, Inc. director Timothy A. Wicks reported an acquisition of 13,889 shares of common stock through a grant of restricted stock units. These units vest on the one-year anniversary of the grant date rather than being immediately transferable.
After this award, Wicks is shown as directly holding 13,889 shares, which include shares to be issued upon the future vesting of one or more restricted stock units. The transaction reflects equity-based compensation rather than an open-market purchase.
MiniMed Group, Inc. director D Keith Grossman reported an equity compensation grant of 13,889 shares of Common Stock on March 9, 2026. The award consists of restricted stock units that vest on the one-year anniversary of the grant date and were granted at no cash cost to him.
Following this grant, Grossman holds 13,889 shares of Common Stock directly, including shares that will be issued upon vesting of one or more restricted stock units. This filing reflects a compensation-related acquisition rather than an open-market stock purchase.
EISENBERG GLENN A reported acquisition or exercise transactions in this Form 4 filing.
MiniMed Group, Inc. director Glenn A. Eisenberg received an equity grant of 13,889 shares of common stock in the form of restricted stock units. The units were awarded at no cash cost and vest on the one-year anniversary of the grant date. Following this award, he directly holds 13,889 shares and units, including shares to be issued upon future vesting of restricted stock units.